- NACDS, NCPA, GPhA express support for Drug Quality and Security Act
- 21 health industry groups address FDA on proposed changes to generic drug label rules
- Generic drug prices spike, but PBMs' reimbursement rates don't keep up, NCPA study finds
- ROUNDTABLE: Improving patient outcomes, controlling costs with OTCs
- Senate passes Drug Quality and Security Act
BALTIMORE — The Food and Drug Administration has approved a generic drug for epilepsy made by Lupin Pharmaceuticals, the drug maker said.
Lupin announced the approval and launch of levetiracetam extended-release tablets in the 500-mg and 750-mg strengths.
The drug is a generic version of UCB's Keppra XR, which had sales of about $161 million during the 12-month period ended in June, according to IMS Health.